ArticleFrontiers in immunology2025
The value of nucleoporin 188 in diagnosis, prognosis and immunoregulation: from pan-cancer analysis to gastric cancer verification.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nucleoporin 188 (NUP188) is a vital component of the nuclear pore complex that regulates cancer progression, but its role in diagnosis, prognosis, and immunoregulation in pan-cancer remains unclear. Methods: A comprehensive exploration of the value of NUP188 was performed using different platforms and software, including TCGA, HPA, UALCAN, TISIDB, cBioPortal, STRING, GSCALite, cancerSEA databases, and R software. The expression of NUP188 in gastric cancer (GC) was detected by immunohistochemistry. The association between NUP188 and clinicopathologic features was explored, and the predictive value of NUP188 was determined. The effect of NUP188 knockdown on the proliferation, migration, and invasion of GC cells was detected Results: NUP188 was dysregulated in most human cancers compared to normal tissues with great diagnostic accuracy. The NUP188 expression was associated with molecular subtype, pathologic stage, prognosis, cancer status, and genomic heterogeneity in multiple cancer types. NUP188 was also related to the immune subtype and infiltrating levels of immune cells. The protein level of NUP188 was both upregulated in GC tissues, and was related to HP infection, depth of invasion, distant metastasis, TNM stage, and overall survival of GC patients. NUP188 interference restrained the proliferation, migration, and invasion of GC cells, and inhibited the GC growth Conclusion: NUP188 plays a potential role in pan-cancer diagnosis and prognosis and may serve as a novel biomarker for tumor immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.